The company ‘ViiV Healthcare’, a global specialist HIV company, which has been majorly owned by GlaxoSmithKline, along with the Shionogi Limited and Pfizer as the major shareholders in the company.
The company has announced that, the US FDA has approved the medicine Cabenuva (rilpivirine cabotegravir) for the purpose of the two-months dosing for the treatment of the HIV-1 in the adults suppressed virologically on a very stable regimen along with no history of the failure of the treatment along with not known resistance either for the rilpivirine or cabotegravir.
Cabenuva has been very first and only complete long acting regimen for the treatment of HIV and had also been the very first approved by the FDA of the United States in the month of February 2022 as a one time in a month treatment for the HIV-1 virologically supressed people.
The Cabenuva has also been containg the cabotegravir of the company, which has been an extended release injectable suspension in a one dose vial and rilpivirine, which has been a product of the company known as the Janssen Sciences Ireland Unlimited Company, which has been one of the pharmaceutical companies of Johnson and Johnson, and the FDA of the United States has also given the authorization that will be allowing Cabenuva for being dosed once in a month or two months.
Lynn Baxter, head of North America at ViiV Healthcare said that, the company has been pleased for continuing their leadership in the research and development of the long acting innovative treatment options for HIV that has been addressing the evolution needs of the community of HIV.
